Group 1 - The core point of the article is that Fuyuan Pharmaceutical (601089.SH) reported its Q3 2025 results, highlighting significant institutional ownership and changes in fund holdings [1] - As of October 29, 2025, a total of 8 institutional investors hold shares in Fuyuan Pharmaceutical, with a combined holding of 361 million shares, representing 75.30% of the total share capital [1] - The institutional ownership decreased by 0.16 percentage points compared to the previous quarter [1] Group 2 - In terms of public funds, 2 new public funds were disclosed this quarter, including E Fund Healthcare Industry Mixed A and Ping An New Xin Pioneer Mixed A [1] - A total of 72 public funds were not disclosed this quarter compared to the previous quarter, including several ETFs and mixed funds [1] - Regarding foreign investment, one foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.26% this quarter [2]

Core Points - The company has announced its third quarter report for 2025, ensuring the accuracy and completeness of the financial information presented [1][6][22] - The board of directors and the supervisory board have approved several key resolutions, including the completion of a high-tech pharmaceutical project and the adjustment of fundraising projects [8][9][27] - The company plans to permanently supplement its working capital with surplus funds from completed projects, amounting to approximately 171.36 million yuan [35][36] Financial Data - The company reported that as of September 30, 2025, it had a total of 12 million shares in its repurchase account, representing 2.50% of the total share capital [3] - The company has not conducted an audit for the third quarter financial statements [1][4] - The financial report includes details on non-recurring gains and losses, which are applicable [1][2] Shareholder Information - The total number of ordinary shareholders and the status of preferred shareholders with restored voting rights were not applicable [2] - The company has outlined the shareholding situation of its top ten shareholders [2] Board Meeting Resolutions - The board meeting held on October 28, 2025, approved the third quarter report and several other significant resolutions [8][9][10] - The board has proposed to cancel the supervisory board and increase the number of board seats, which will require shareholder approval [15][30] Project Adjustments - The company has completed the high-tech pharmaceutical project and plans to use the remaining funds for daily operations [35][36] - Adjustments to the innovative drug and generic drug research projects have been made, with some projects being postponed until December 2026 [40][43] Upcoming Shareholder Meeting - The second extraordinary general meeting of shareholders is scheduled for November 14, 2025, with both onsite and online voting options available [58][59]

Group 1 - The company, Fuyuan Pharmaceutical, announced the convening of its third board meeting on October 28, 2025, to discuss the senior management compensation plan [1] - For the fiscal year 2024, the revenue composition of Fuyuan Pharmaceutical is as follows: 93.12% from pharmaceutical preparations, 6.46% from medical devices, 0.36% from other businesses, and 0.06% from other sources [1] - As of the report date, Fuyuan Pharmaceutical has a market capitalization of 10.6 billion yuan [1]

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 2.521 billion yuan, representing a year-on-year decrease of 1.04% [1] - The net profit attributable to shareholders of the parent company was 375 million yuan, down 6.39% year-on-year [1] - The basic earnings per share stood at 0.78 yuan [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-075 北京福元医药股份有限公司 关于公司参与第十一批全国药品集中采购 拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 10 月 27 日至 10 月 28 日，北京福元医药股份有限公司（以下简称"公 司"）参加了国家组织药品联合采购办公室（以下简称"联采办"）组织的第十一 批全国药品集中采购的投标工作。经联采办开标、评标后，公司 6 个产品拟中标本 次集中采购，现将相关情况公告如下： | 序号 | 品种名称 | 药品适应症 | 规格包装 | 拟中选价格 | 用于成年人和青少 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 富 | 马 | 酸 | 卢 | 帕 | 他 | 年（12 | 岁以上）过 | 1 | 10mg*30 | 片 | 32.59 | 元 ...

中信建投证券股份有限公司关于北京福元医药股份有限公司 部分募投项目结项并将节余募集资金永久补充流动资金及调整募投 项目部分实施内容并延期的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为北京福元医药股份有限公司（以下简称"福元医药"、"公司"）首次公开 发行股票并上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等相关规定履行持续 督导职责，对福元医药部分募投项目结项并将节余募集资金永久补充流动资金及 调整募投项目部分实施内容并延期的情况进行了审慎核查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准北京福元医药股份有限公司首次公 开发行股票的批复》（证监许可[2022]974号）核准，公司首次公开发行人民币 普通股（A股）股票12,000万股，发行价格为人民币14.62元/股，募集资金总额 为人民币1,754,400,000.00元，扣除不含增值税发行费用人民币118,480,188.68元 后，募集资金净额为人民币1,635,919,811.32元。 首次公开发行股票的募集资金于2 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) announced that six of its products are expected to be selected in the 11th national centralized drug procurement, which could enhance market share and positively impact future operating performance [1] Group 1: Product Selection - The six products include: Fumaric Acid Lurasidone Tablets, Pravastatin Sodium Tablets, Silodosin Tablets, Alendronate Sodium Tablets, Agomelatine Tablets, and Dopamine Hydrazine Tablets [1] - If these products are selected and sales contracts are signed, it will contribute to an increase in market share for the company [1] Group 2: Financial Impact - The products that were not selected, such as Dapagliflozin Tablets, did not generate sales in 2024 and had sales of 2.9413 million yuan from January to September 2025, accounting for 0.1167% of the company's revenue during the same period [1] - The lack of selection for these products is not expected to have a significant impact on the company's production and operations [1]

北京福元医药股份有限公司对外投资管理制度 第一章 总则 第一条 为规范北京福元医药股份有限公司（以下简称"公司"）的投资行为， 控制投资风险，提高投资收益，实现投资决策的规范化、科学化、制度化，保障 公司资金运营的安全性和收益性，根据《中华人民共和国公司法》《上海证券交 易所股票上市规则》《上市公司治理准则》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》《上海证券交易所上市公司自律监管指引第 5 号——交 易与关联交易》以及《北京福元医药股份有限公司章程》（以下简称《公司章程》） 等有关规定，结合公司实际情况，制定本制度。 第二条 本制度所指的投资专指对外投资，包括将货币资金以及经资产评估 后的房屋、机器、设备、物资等实物，以及专利权、商标权、土地使用权等无形 资产作价对外直接投资，也包括委托理财、委托贷款、证券与衍生品投资等以寻 求短期差价为主要目的的投资活动，具体包括但不限于： （一）与境内外其他单位进行联营、合营； （七）法律、法规规定的其他对外投资。 第三条 本制度所称证券投资，包括新股配售或者申购、证券回购、股票及 存托凭证投资、债券投资、委托理财以及上海证券交易所认定的其他投资行为 ...

北京福元医药股份有限公司独立董事工作制度 第一章 总则 第一条 为进一步完善北京福元医药股份有限公司（以下简称"公司"）的 治理结构，促进公司的规范运作，充分发挥独立董事的作用，根据中国证券监督 管理委员会《上市公司独立董事管理办法》（以下简称"《管理办法》"）、《上 海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第1号— —规范运作》等法律、法规、规范性文件和《北京福元医药股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及公司 主要股东（持有公司5%以上股份，或者持有股份不足5%但对公司有重大影响的股 东）、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立 客观判断关系的董事。独立董事应当独立履行职责，不受公司及其主要股东、实 际控制人等单位或者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按 照《管理办法》《公司章程》以及其他法律法规和本制度的要求，认真履行职责， 在公司董事会中发挥参与决策、监督制衡、专业咨询作用，维护公司整体利益， 尤其关注中小股东的合法 ...

北京福元医药股份有限公司对外担保管理制度 第一章 总则 第一条 为规范北京福元医药股份有限公司（以下简称"公司"）对外担保管 理，规范公司担保行为，控制公司经营风险，根据《中华人民共和国民法典》《中 华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上市公司监管 指引第 8 号——上市公司资金往来、对外担保的监管要求》等有关法律、行政法 规、规范性文件及《北京福元医药股份有限公司章程》（以下简称"《公司章程》"） 第二条 本制度所称对外担保是指公司以第三人身份为他人提供的保证、抵 押或质押，公司为子公司提供的担保视为对外担保。 第三条 公司合并报表范围内子公司的对外担保，视同公司行为，其对外担 保应执行本制度。 第四条 公司对外担保实行统一管理，未经公司董事会或股东会批准，任何 人无权以公司名义签署对外担保的合同、协议或其他类似的法律文件。 第五条 公司董事和高级管理人员应审慎对待和严格控制担保产生的债务风 险，并对违规或失当的对外担保产生的损失依法承担连带责任。 第六条 公司对外担保应当遵循合法、审慎、互利、安全的原则， ...